Acceptability of a Fixed Combination of Fenofibrate and Metformin

Solvay

Status and phase: Completed; Phase 3

Conditions: Dyslipidemia/Glucose Metabolism Disorder

Treatments: Drug: fenofibrate and metformin fixed combination (drug)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00348725

C LF23-0121 04 02

Details and patient eligibility

About

The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes mellitus and dyslipidemia.

Exclusion criteria

• Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose > 300 mg/dL - Triglycerides > 500 mg/dL

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)